PTC Therapeutics, Inc. Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities
PTC Therapeutics, Inc. (PTCT) reported Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities of 5.46 million shares for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities · last filed 2026-07-30
- PTC Therapeutics, Inc. incremental common shares attributable to dilutive effect of conversion of debt securities for the quarter ending 2026-06-30 was 5.46M shares.
- PTC Therapeutics, Inc. incremental common shares attributable to dilutive effect of conversion of debt securities for the quarter ending 2025-09-30 was 5.47M shares.
- PTC Therapeutics, Inc. incremental common shares attributable to dilutive effect of conversion of debt securities for the quarter ending 2025-03-31 was 5.47M shares.
- PTC Therapeutics, Inc. incremental common shares attributable to dilutive effect of conversion of debt securities for fiscal 2025 was 5.47M shares.
| Period end | Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities 3 month | Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities 6 month | Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities 9 month | Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities 12 month |
|---|---|---|---|---|
| 2026-06-30 | 5.46M shares 10-Q · filed 2026-07-30 | 5.47M shares 10-Q · filed 2026-07-30 | ||
| 2025-12-31 | 5.47M shares 10-K · filed 2026-02-19 | |||
| 2025-09-30 | 5.47M shares 10-Q · filed 2025-11-04 | 5.47M shares 10-Q · filed 2025-11-04 | ||
| 2025-06-30 | 5.47M shares 10-Q · filed 2026-07-30 | |||
| 2025-03-31 | 5.47M shares 10-Q · filed 2026-05-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |